⚠️
od 10/2026 nowa terapia: enkorafenib + cetuksymab (2. i kolejne linie, BRAF V600E)
Terapie w programie lekowym:
Leki w katalogu chemioterapii:
Aflibercept
Bevacizumab
Capecitabine
Capecitabine (2)
Carboplatin
Cetuximab
Cisplatinum
Cyklophosphamidum
Dacarbazinum
Denosumab
Doxorubicinum
Etoposidum
Fluorouracilum
Ifosfamidum
Imatinibum
Irinotecanum
Kabozantynib
Lanreotidum
Octreotidum
Oxaliplatinum
Paclitaxel
Panitumumab
Regorafenib
Sorafenib
Sunitinib
Temozolomidum
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- colorectal cancer
- rectal cancer
- » An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
- » A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
- » A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- » A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- » A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)